RhoH is a hematopoietic-specific, GTPase-deficient member of the Rho GTPase family that functions as a regulator of thymocyte development and T-cell receptor signaling by facilitating localization of zeta-chain-associated protein kinase 70 (ZAP70) to the immunological synapse. Here we investigated the function of RhoH in the B-cell lineage. B-cell receptor (BCR) signaling was intact in Rhoh À/À mice. Because RhoH interacts with ZAP70, which is a prognostic factor in B-cell chronic lymphocytic leukemia (CLL), we analyzed the mRNA levels of RhoH in primary human CLL cells and showed a 2.3-fold higher RhoH expression compared with normal B cells. RhoH expression in CLL positively correlated with the protein levels of ZAP70. Deletion of Rhoh in a murine model of CLL (El-TCL1 Tg mice) significantly delayed the accumulation of CD5 þ IgM þ leukemic cells in peripheral blood and the leukemic burden in the peritoneal cavity, bone marrow and spleen of Rhoh À/À mice compared with their Rhoh þ / þ counterparts. Phosphorylation of AKT and ERK in response to BCR stimulation was notably decreased in El-TCL1 Tg ;Rhoh À/À splenocytes. These data suggest that RhoH has a function in the progression of CLL in a murine model and show RhoH expression is altered in human primary CLL samples.
Introduction
B-cell chronic lymphocytic leukemia (CLL) represents the most common leukemia in adults and a disease for which there are no curative treatments available. 1 The disease is characterized by the clonal expansion of small mature-appearing CD19 þ CD5 þ CD23 þ B cells in the peripheral blood, bone marrow, lymph nodes and other lymphatic tissues. The absence of somatic mutations in the immunoglobulin heavy-chain variable region (IGHV) genes and expression of the zetachain-associated protein kinase 70 (ZAP70) are strongly associated with an aggressive clinical course. 2, 3 ZAP70, a nonreceptor tyrosine kinase that has a central function in T-cell receptor (TCR) signal transduction, is abnormally expressed in aggressive CLL and has been shown to enhance B-cell receptor (BCR) signaling in CLL cells. [4] [5] [6] These and other data suggest that signaling through the BCR is important in CLL pathogenesis. 1 Rho GTPases represent a family of proteins that has key functions in intracellular signaling and regulate cellular morphology, motility and proliferation. 7 Although most Rho GTPases cycle between GTP-bound active and GDP-bound inactive states, RhoH, an hematopoietic-specific member of the RhoE subfamily, is GTPase-deficient and therefore remains in the active GTP-bound state. 8 Along with others, we have previously described the critical interaction of ZAP70 with the small GTPase RhoH in TCR function. 9, 10 In T cells, RhoH functions as a critical regulator of thymocyte development and TCR signaling by mediating recruitment of ZAP70 to the immunological synapse. RhoH is required for phosphorylation of CD3z, membrane translocation of ZAP70 and subsequent activation of ZAP70-mediated pathways. 9 RhoH serves as an adaptor molecule for ZAP70 and Lck in TCR signaling (Chae et al., in review) and contains functional immunoreceptor tyrosine-based activation (ITAM)-like motifs. 9 Thus RhoH is unique among Rho GTPases in that the cellular activity is dependent on expression levels and post-translational modification of the protein.
Several lines of evidence link dysregulation of RhoH to the development of malignancies. The RHOH gene was first identified in a non-Hodgkin's lymphoma cell line harboring a t(3;4)(q27;p11) translocation 11 and rare chromosomal alterations involving the RHOH gene have been detected in cases of follicular lymphoma and multiple myeloma. 12 Moreover, similar to other well-characterized protooncogenes (BCL6, MYC, PAX5), the 5 0 -noncoding region of the RHOH gene is a target of somatic hypermutation in a variety of B-lymphoid malignancies such as diffuse large B-cell lymphomas, 13, 14 AIDSrelated non-Hodgkin's lymphomas 15 and primary central nervous system lymphomas. 16 Although these studies have suggested a possible function of RhoH dysregulation in malignant transformation, a direct demonstration of the involvement of RhoH in cancer initiation or progression has not been provided.
Here we examined the function of RhoH in physiological and malignant B-cell lineages. Although the development of B cells is only minimally perturbed in the absence of RhoH, an analysis of primary human CLL cells revealed significantly higher RhoH expression levels than in normal B cells. Moreover, the expression level of RhoH correlates with the protein levels of ZAP70. To further investigate the function of RhoH in the development and progression of CLL, we used a genetic mouse model of CLL, the Em-TCL1-transgenic mouse. 17 In this model, the expression of the TCL1 oncogene is targeted to the B-cell lineage, resulting in the expansion of the B-1 cell compartment and the development of CD5 þ B-cell leukemia, resembling the aggressive form of human CLL. 17, 18 Deletion of Rhoh in the Em-TCL1 background results in a significant delay of disease progression, highlighting the critical function of RhoH in CLL pathogenesis.
Materials and methods

Patients and cell samples
The human samples for this study were obtained after informed consent and with approval of the institutional review boards of the 
RhoH mRNA measurement by quantitative real-time PCR
Total RNA from CLL and normal human B-cell samples was isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Aliquots of 1 mg total RNA were reverse transcribed using the Protoscript First Strand cDNA synthesis kit (New England Biolabs, Ipswich, MA, USA).
Quantitative real-time polymerase chain reaction (PCR) was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in an ABI Prism 7700 Sequence Detector System (Applied Biosystems). Primer sequences for RhoH amplification were 5 0 -TTGATTTCCGGAGT CAGTCA-3 0 (forward) and 5 0 -GTTCTCCACGGCTTCAGTTT-3 0 (reverse). Phosphoglycerate kinase 1 (PGK1) was amplified as an endogenous control, using the following primers: 5 0 -GGGAAAA GATGCTTCTGGGAA-3 0 (forward) and 5 0 -TTGGAAAGTGAAG CTCGGAAA-3 0 (reverse).
Mice
The generation of Rhoh À/À mice has been previously described. 9 The 129/Sv Rhoh À/À strain was backcrossed on the C57BL/6J background. Mice used were derived from more than 20 backcross generations and were 7-14 weeks of age.
To investigate the function of RhoH in a murine model of CLL, we crossed Em-TCL1 Tg/Tg mice on a mixed B6C3 background 17 with Rhoh À/À mice. The resulting F1 mice were either crossed with Rhoh À/À mice, yielding Em-TCL1-transgenic mice nullizygous or heterozygous for Rhoh (Em-TCL1 Tg ;Rhoh À/À or Em-TCL1 Tg ;Rhoh þ /À ) and their nontransgenic littermates (Rhoh À/À , Rhoh þ /À ), or we crossed them with wild-type (WT) C57BL/6J mice, yielding Em-TCL1-transgenic mice with normal Rhoh alleles (Em-TCL1 Tg ;Rhoh þ / þ ) and their nontransgenic littermates (Rhoh þ / þ ). All experiments involving animals were approved by the Institutional Animal Care and Use Committee of the Cincinnati Children's Research Foundation (Cincinnati, OH, USA).
Flow cytometry
For flow cytometry analysis, the following antibody conjugates were used: B220-APC-Cy7 (RA3-6B2), CD19-PE-Cy7 (1D3), CD43-PE (S7), IgM-PerCP-Cy5.5 (R6-60.2), IgM-APC (II/41), IgD-FITC (11-26c.2a), CD3e-PE(145-2C11), CD21/CD35-PE (7G6), CD69-FITC (H1.2F3; all from BD Biosciences, San Jose, CA, USA); CD93-APC (AA4.1) and CD5-PE-Cy7 (53-7.3; both from eBioscience, San Diego, CA, USA). Red blood cells were lysed by incubation in BD PharmLyse (BD Biosciences) for 10 min, and the resulting cell suspensions were incubated at 4 1C for 30 min with a 1:100 dilution of the appropriate conjugates. After staining, cells were washed and resuspended in phosphate-buffered saline (PBS). In some assays, 7-AAD (2 mg/ml) was added to the resuspension solution for dead cell exclusion. For apoptosis assays, cells were stained with 7-AAD and Annexin V-FITC (BD Biosciences). Cells were analyzed on a FACSCanto flow cytometer (BD Biosciences).
Immunophenotyping of normal murine B-cell populations
Single-cell suspensions were prepared from bone marrow, spleen, lymph nodes, peripheral blood and peritoneal cavity of WT and Rhoh À/À mice. Cells were stained using fluorescently labeled antibodies and analyzed by flow cytometry. B-cell differentiation stages of normal B cells in the bone marrow were defined as follows:
In secondary lymphoid organs, B cells were classified as transitional (B220 þ CD93 þ ), B-2/follicular (B220 þ CD93 À IgD hi CD21 lo ) and marginal zone (MZ) B cells (B220 þ CD93 À IgD lo CD21 hi ). Peritoneal B-1 cells were defined as B220 lo IgM þ CD5 þ .
Immunophenotyping of murine leukemic cells
The peripheral blood immunophenotype of Em-TCL1 Tg mice was monitored longitudinally in a cohort of mice (Em-TCL1 Tg ;Rhoh þ / þ , Em-TCL1 Tg ;Rhoh þ /À , Em-TCL1 Tg ;Rhoh À/À with n ¼ 5-19 mice per time point, and their respective nontransgenic littermate controls). Starting at 2 months of age, peripheral blood was obtained monthly from the tail veins of the mice. Additional mice were killed at 6 months of age to investigate the degree of leukemic infiltration of the bone marrow, spleen and peritoneal cavity at a defined time point. CLL cells were defined as CD3 À CD5 þ IgM þ . The leukemic burden was expressed as the total number of CD3 À CD5 þ IgM þ cells at each anatomical site.
Isolation of normal murine splenic B cells
Resting B cells were purified from splenic single-cell suspensions by negative selection using mouse CD43 Microbeads and LD columns (Miltenyi Biotec), following the manufacturer's recommendations. In all experiments, a pool of cells from two to three mice of each genotype was used. The purity of the negative fractions was checked by flow cytometry (B220 þ ) and was typically higher than 95%. For subfractionation of B-2 and MZ B cells, CD43-depleted fractions were stained with FITC-conjugated anti-IgD and PE-conjugated anti-CD21/CD35 and sorted on a FACSVantage flow cytometer. B-2 cells were defined as IgD hi CD21 lo and MZ B cells as IgD lo CD21 hi .
In vitro activation and proliferation of murine B cells
For in vitro assays, purified splenic B cells were plated in 96-well plates at a concentration of 2 Â 10 6 cells per ml in IMDM containing 10% FBS (Omega Scientific, Tarzana, CA, USA), penicillin/streptomycin (Hyclone, Waltham, MA, USA), 2 mM L-glutamine (Invitrogen), and the appropriate stimuli. These included lipopolysaccharide (LPS) from Escherichia coli (2 or 20 mg/ml; Sigma-Aldrich), F(ab') 2 goat anti-mouse IgM (1 or 10 mg/ml; Jackson ImmunoResearch, West Grove, PA, USA), affinity purified anti-mouse CD40 (2 mg/ml; clone 1C10; eBioscience), murine recombinant IL-4 (Peprotech, Rocky Hill, NJ, USA), or combinations thereof.
B-cell activation was measured by flow cytometric detection of the activation antigen CD69 after 20 h of stimulation. Proliferation was determined by [ 3 H]-thymidine incorporation. Briefly, splenic B cells were cultured in the presence of 2 or 20 mg/ml LPS for 48 h in triplicates, and then pulsed with 1 mCi of [ 3 H]-thymidine (GE Healthcare, Buckinghamshire, UK) for 12 h. Incorporation of [ 3 H]-thymidine was measured in a scintillation counter (Beckman, Fullerton, CA, USA). The production of IgM in the culture supernatant was quantified by enzyme-linked immunosorbent assay (ELISA) after 48 h of stimulation.
Chemotaxis assays
Splenic B cells (1 Â 10 6 cells in 100 ml complete medium) were seeded in triplicate in the upper chamber of 24-well, 5-mm Transwell plates (Corning, Corning, NY, USA) in which the lower chamber contained 600 ml of complete medium supplemented with CXCL12 (Peprotech) or CXCL13 (R&D Systems, Minneapolis, MN, USA) and incubated for 4 h at 37 1C. Cells that migrated to the lower chamber were collected and counted using a hemocytometer. The results were expressed as the percentage of migrated cells, relative to the total number of input cells.
ELISA
The concentration of different immunoglobulin isotypes (IgM, IgG 1 , IgG 3 ) in serum or in culture supernatants were determined by ELISA using isotype-specific antibodies (Mouse IgM, IgG 1 and IgG 3 quantitation kits; Bethyl Laboratories, Montgomery, TX, USA), following the manufacturer's recommendations.
Analysis of BCR signaling
For the analysis of protein phosphorylation, prewarmed normal splenic B cells or leukemic splenocytes from mice 6-15 months of age were stimulated with 25 mg/ml F(ab') 2 goat anti-mouse IgM (Jackson ImmunoResearch) for 1 or 5 min at 37 1C, washed in cold PBS, lysed and analyzed by western blotting.
Intracellular calcium flux was measured by flow cytometry. Cells (3 Â 10 6 ) were stained with 2.5 mM Fluo-3 (Invitrogen) in Tyrode's salt solution (Sigma-Aldrich) at 37 1C for 45 min, washed twice, resuspended in 450 ml of Tyrode's buffer and incubated at 37 1C for another 30 min. Baseline fluorescence (FITC channel) was measured for 30 s before the addition of 2.5 or 25 mg/ml F(ab') 2 goat anti-mouse IgM (Jackson Immuno-Research), after which data acquisition was continued for 5-10 min.
Immunoblotting
For western blotting, cells were lysed in radioimmuno precipitation assay buffer (10 mM Tris-HCl (pH 7.4), 130 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate) containing protease and phosphatase inhibitors (5 mM EDTA, 5 mM EGTA, 10 mM NaF, 10 mM b-glycerophosphate, 1 mM sodium ortovanadate and Complete protease inhibitor cocktail; Roche Applied Science, Indianapolis, IN, USA). The following primary antibodies were used (all of them at a 1:1000 dilution): ZAP70 (99F2); phospho-p44/p42 MAPK (Thr202/Tyr204; 197G2), p44/p42 MAPK, phospho-JNK (Thr183/Tyr185), JNK, phospho-p38 (Thr180/Tyr182; 28B10), p38, phospho-AKT (Ser473), AKT; phospho-SYK (Tyr525/526), SYK (all from Cell Signaling Technology, Danvers, MA, USA); b actin (AC-15; Sigma-Aldrich; 1:10 000 dilution) was used as a loading control.
Statistical analysis
Differences between CLL and normal B cells with respect to RhoH expression, and differences in leukemic cell counts between Em-TCL1 Tg ;Rhoh þ / þ and Em-TCL1 Tg ;Rhoh À/À mice at 6 months of age were tested by exact Wilcoxon tests. The correlation between ZAP70 and RhoH expression was estimated by the Pearson correlation coefficient. The difference between Em-TCL1 Tg ;Rhoh þ / þ , Rhoh þ /À and Rhoh À/À groups with respect to the logarithm of cell count profiles over time was tested by comparisons of linear random effects models. 19 Tests and models were fit using the univariate, corr and mixed procedures of SAS 9.1 (SAS Institute, Cary, NC, USA). 20 All P-values were two-sided. Data with P-values lower than 0.05 were considered significant.
Results
Characterization of the B-cell compartment of Rhoh À/À mice
We performed a detailed analysis of B-cell subsets and differentiation stages in Rhoh À/À mice. Rhoh À/À mice showed modestly elevated B-cell numbers in the bone marrow (7.8±1.8 Â 10 6 vs 11.0±2.4 Â 10 6 cells per 2 tibias and 2 femurs, WT vs Rhoh À/À ; Po0.05). There was an increase in the number of pro- Figure 1a ; Table 1 ). In the spleen, Rhoh À/À mice showed a reduced number of B-2 cells (B220 þ CD93 À IgD hi CD21 lo ) (65% of WT; Figure 1b ). The B-2 compartment was also significantly diminished in peripheral blood (Figure 1c ) and lymph nodes (Supplementary Figure 1A) . The number of B-1 cells (B220 lo IgM þ CD5 þ ) in the peritoneal cavity of Rhoh À/À mice was comparable to that in WT animals (Supplementary Figure  1B) . Analysis of the serum concentrations of immunoglobulin isotypes revealed dramatically decreased levels of IgG 1 (Po0.001) ( Figure 1d ). The in vitro activation of splenic B cells using anti-IgM, LPS, anti-CD40 or IL-4 as agonists and the in vitro proliferation in response to LPS was not significantly different between WT and Rhoh À/À mice ( Supplementary  Figures 2A-C) . Chemotaxis in response to CXCL12 (100 ng/ml) and CXCL13 was similar between WT and Rhoh À/À B cells (Supplementary Figure 2D) although Rhoh À/À cells appeared to show decreased migration at higher concentrations of CXCL12 (data not shown). These data suggest a modest effect of RhoH on B-cell development. Given the normal in vitro proliferative and chemotaxis responses to multiple B-cell agonists, and previously We have previously documented the critical function of RhoH in TCR signal transduction. 9 In contrast, we did not observe major perturbations in signaling in Rhoh À/À B cells in response to BCR agonist. Rhoh À/À B cells appeared to show increased intracellular calcium flux following weak BCR stimulation, but this difference was not observed at higher concentration of anti-IgM ( Supplementary Figure 3) . Loss of RhoH did not impair protein tyrosine phosphorylation after BCR ligation (Supplementary Figure 4A ). Moreover, several downstream components of the BCR pathway (SYK, ERK, JNK, p38) appeared to be hyperphosphorylated in the absence of RhoH when the analysis was performed on total splenic B cells (Supplementary Figure   Figure 1 B-cell subsets in WT and Rhoh À/À mice. Analysis was by multiparameter flow cytometry, and absolute cell numbers were calculated using the total cellularity of each organ. RhoH is critical in the development of CLL A Sanchez-Aguilera et al 4B). However, the phosphorylation of spleen tyrosine kinase (SYK) or extracellular signal-regulated kinase (ERK) in sorted populations of B-2 (IgD hi CD21 lo ) and MZ (IgD lo CD21 hi ) B cells from Rhoh À/À and WT mice did not differ in response to BCR cross-linking (Figure 1e) , implying that the observed differences can be explained by the different cellular composition of the B-cell compartment (B-2 vs MZ B cells). In summary, Rhoh À/À B cells showed only modest variations of subtype distribution and no significant alteration of BCR signaling. Taken together, these data are consistent with a mild in vivo B-cell differentiation impairment with no obvious B-cell intrinsic signaling defect.
Elevated RhoH expression in primary human CLL cells
We have previously described the interaction between RhoH and ZAP70 in the TCR signaling pathway. 9 ZAP70 is expressed in human CLL, is a negative prognostic factor in this disease 2, 3 and regulates BCR signaling in CLL cells. [4] [5] [6] Therefore, we next investigated the potential function of RhoH in CLL. The mRNA expression levels of RhoH in primary human CLL cells (CD19 þ CD5 þ ), as determined by real-time PCR, were significantly higher than in CD19 þ peripheral blood B cells obtained from healthy donors (40.48 ± 22.28 vs 18.22 ± 7.95, CLL (n ¼ 29) vs normal B cells (n ¼ 6), Po0.05) (Figure 2a ). No correlation was observed between RhoH expression and disease stage or leukocyte count. To determine whether RhoH levels were related to ZAP70 expression, we analyzed the protein levels of ZAP70 in CLL samples by immunoblotting. There was a significant, positive correlation between ZAP70 and RhoH expression (Pearson correlation coefficient of 0.42, Po0.05) (Figure 2b ). Together, these observations imply that RhoH expression is elevated in human CLL and may be associated with the aggressive form of the disease.
RhoH involvement in the development of CLL in the Em-TCL1-transgenic CLL model
To further delineate the potential function of RhoH in CLL, we crossed Rhoh À/À mice with Em-TCL1-transgenic mice. 17 These mice express the TCL1 oncogene in a B-cell-specific fashion and accumulate abnormal numbers of CD5 þ IgM þ B cells progressively in multiple organs leading to death from tumor infiltration. Moreover, leukemic clones in these mice display very low levels of Ig somatic hypermutation, recapitulating the aggressive, unmutated form of human CLL. 21 Starting at 2 months of age, the number of CD5 þ IgM þ CLLlike cells in peripheral blood was monitored in Em-TCL1- .05 (Em-TCL1 Tg ;Rhoh þ /À vs Em-TCL1 Tg ;Rhoh À/À ). Globally, the three leukemic cell count profiles (Em-TCL1 Tg ;Rhoh þ / þ , Rhoh þ /À and Rhoh À/À ) over time were significantly different (Po0.001). All pair-wise comparisons were also significantly different: Rhoh þ / þ vs Rhoh þ /À (P ¼ 0.006), Rhoh þ / þ vs Rhoh À/À (Po0.001) and Rhoh þ /À vs Rhoh À/À (P ¼ 0.017). (b) Number of CD5 þ IgM þ cells in the spleen, bone marrow (BM) and peritoneal cavity (PC) of Em-TCL1 Tg ;Rhoh þ / þ and Em-TCL1 Tg ;Rhoh À/À analyzed at 6 months of age. Data represent mean±s.e.m. n ¼ 4-7. Differences were statistically significant for BM ( n Po0.05) and showed a trend in the same direction for spleen (P ¼ 0.11) and PC (P ¼ 0.31). transgenic, Rhoh þ / þ , Rhoh þ /À and Rhoh À/À mice (Figure 3a) . In Em-TCL1-transgenic mice with normal RhoH alleles (Em-TCL1 Tg ;Rhoh þ / þ ) or with one Rhoh allele (Em-TCL1 Tg ; Rhoh þ /À ), abnormal accumulation of CD5 þ IgM þ B cells was observed at 4 months, and the number of these cells increased dramatically thereafter. In contrast to normal murine B cells, splenic B cells from Em-TCL1 Tg ;Rhoh þ / þ mice showed easily detectable ZAP70 by immunoblot (data not shown). The number of CD5 þ IgM þ B cells was significantly lower in Em-TCL1 Tg ;Rhoh þ /À compared with Em-TCL1 Tg ;Rhoh þ / þ mice, suggesting a gene-dosage effect of RhoH expression. In contrast, Em-TCL1 Tg mice nullizygous for Rhoh (Em-TCL1 Tg ;Rhoh À/À ) showed no significant increase in the number of CD5 þ IgM þ B cells until 5 months of age, and the disease burden remained significantly lower than in RhoH-expressing counterparts throughout the entire follow-up time (8 months). The three leukemic cell count profiles (Em-TCL1 Tg ;Rhoh þ / þ , Rhoh þ /À and Rhoh À/À ) over time were significantly different (Po0.001). As expected, no increase of CD5 þ IgM þ B cells was observed in the nontransgenic controls (Rhoh þ / þ , Rhoh þ /À and Rhoh À/À ; data not shown).
To determine if these differences in peripheral blood represent abnormal distribution of cells or reduced production or survival of these cells, we assessed the number of CD5 þ IgM þ cells in peritoneal cavity, spleen and bone marrow in a cohort of mice at 6 months of age (n ¼ 4-7; Figure 3b ). Leukemic burden was significantly decreased in the bone marrow of Em-TCL1 Tg ;Rhoh À/À compared with Em-TCL1 Tg ;Rhoh þ / þ mice (5.4-fold reduction, Po0.05) and showed a clear trend in the same direction in the spleen (2.4-fold reduction) and peritoneal cavity (2.4-fold reduction), although it did not reach statistical significance.
To determine whether the decreased leukemic burden was associated with reduced cell survival, we measured the levels of apoptosis in B-1/CLL cells in Em-TCL1 Tg ;Rhoh þ / þ and Em-TCL1 Tg ;Rhoh À/À mice. The fraction of apoptotic, CD5 þ IgM þ peritoneal cells at 2 months of age did not significantly differ between Em-TCL1 Tg ;Rhoh þ / þ and Em-TCL1 Tg ;Rhoh À/À mice (10.25±2.54% vs 12.85±3.43% annexin V þ 7-AAD À cells, n ¼ 4, P ¼ 0.27). However, CD5 þ IgM þ splenocytes in 6-to 8-month-old Em-TCL1 Tg ;Rhoh À/À showed higher levels of apoptosis (21.3 ± 7.95% annexin V þ 7-AAD À cells, n ¼ 4) compared with Em-TCL1 Tg ;Rhoh þ / þ mice (10.5%, n ¼ 2). Impaired BCR-induced AKT and ERK phosphorylation in Em-TCL1 Tg ;Rhoh À/À splenocytes To gain mechanistic insight into the impaired leukemia development in the absence of RhoH, we analyzed the activation of several components of the BCR signal transduction pathway in splenocytes from three Em-TCL1 Tg ;Rhoh þ / þ , two Em-TCL1 Tg ;Rhoh þ /À and four Em-TCL1 Tg ;Rhoh À/À mice (Figure 4) . In contrast to nontransgenic Rhoh À/À B cells, which showed normal AKT activation after BCR cross-linking (Supplementary Figure 4B ), basal and agonist-induced phosphorylation of AKT (Ser473) was clearly diminished in Em-TCL1 Tg ;Rhoh À/À cells compared with their Rhoh þ / þ counterparts (Figures 4a  and b) . Also, BCR-induced phosphorylation of ERK was clearly reduced in the absence of Rhoh (Figures 4a and c) . Figure 4 Impaired B-cell receptor (BCR)-induced AKT and ERK phosphorylation in Em-TCL1 Tg ;Rhoh À/À splenocytes. (a) Analysis of BCR signaling in splenocytes from Em-TCL1 Tg ;Rhoh þ / þ and Em-TCL1 Tg ;Rhoh À/À mice. Cells were stimulated with 25 mg/ml anti-IgM for 1 or 5 min and analyzed by immunoblotting. (b) Densitometric quantification of AKT (Ser473) phosphorylation in splenocytes from Em-TCL1 Tg ;Rhoh þ / þ (n ¼ 3), Em-TCL1 Tg ;Rhoh þ /À (n ¼ 2) and Em-TCL1 Tg ;Rhoh À/À mice (n ¼ 4). Values were normalized with total AKT expression. (c) Densitometric quantification of ERK (Thr202/Tyr204) phosphorylation in splenocytes from Em-TCL1 Tg ;Rhoh þ / þ (n ¼ 3), Em-TCL1 Tg ;Rhoh þ /À (n ¼ 2) and Em-TCL1 Tg ;Rhoh À/À mice (n ¼ 4). Values were normalized with total ERK expression. In (b) and (c), one of the samples was used as a calibrator to allow normalization across different gels. z , not determined.
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Discussion
RhoH is a hematopoietic-specific, GTPase-deficient member of the Rho GTPase family with high expression in lymphoid tissues. 8, 22 RhoH has been shown to have an essential function in thymocyte development and TCR signaling. 9, 10 In spite of the fact that RhoH is also expressed in B cells (data not shown), deletion of murine Rhoh does not substantially alter physiological B-cell development in vivo, although changes in B-cell numbers are seen in Rhoh À/À mice, probably related to T-cell compartment abnormalities previously reported. 9 Supporting this view, RhoH does not seem to have an essential function in B-cell activation, chemotaxis or BCR signaling in vitro.
In T cells, RhoH functions as a facilitator of ZAP70 recruitment to the TCR and the immunological synapse 9 (Chae et al., in review). Normal B cells express lower levels of ZAP70 compared with T cells, 23 and BCR signal transduction is thought to be mainly mediated by the related protein tyrosine kinase, SYK. 24, 25 SYK is recruited to the phosphorylated ITAM motifs of the activated BCR complex where it is activated by Src-family kinases, 24 thus having a somewhat parallel function to that of ZAP70 in TCR signaling. The different requirement of RhoH in T-and B-cell antigen receptor complexes likely reflects structural or biochemical dissimilarities between ZAP70 and SYK and/or differences in regulation of the two signaling complexes. For instance, SYK has much higher intrinsic tyrosine kinase activity than ZAP70, 26 and it can initiate immunoreceptor signaling in the absence of Src-related kinases. 27 In contrast to normal B cells, ZAP70 is aberrantly expressed in the malignant cells of CLL with unmutated IGHV status and is associated with poor prognosis. 2, 3 The reported observations that RhoH interacts with ZAP70 9 and that genetic alterations of RHOH, similar to those affecting bona fide protooncogenes (chromosomal translocations and aberrant somatic hypermutation), occurring in B-lymphoid malignancies, 12, 13, 15, 16 prompted an examination of the function of RhoH in CLL. Indeed, RhoH was overexpressed in a subset of primary human CLL and the expression of RhoH was correlated to the protein levels of ZAP70, suggesting that RhoH might have a function in the pathogenesis of the disease. We did not observe significant differences in the expression of RhoH between CLL patients with mutated and unmutated IGHV genes (data not shown).
To directly investigate the function of RhoH in CLL in vivo, we used the Em-TCL1-transgenic mouse 17, 18 as a model of the aggressive, IGHV-unmutated subtype of CLL, which in humans correlates with high ZAP70 expression. Although TCL1 is not genetically altered in human CLL, it is expressed in the majority of the cases, and high levels of TCL1 correlate with ZAP70 expression and unmutated IGHV genes. 28, 29 Inactivation of Rhoh in the Em-TCL1 genetic background significantly delayed disease progression as measured by the accumulation of CD5 þ IgM þ cells in peripheral blood and lymphoid tissues. As implied by the analysis of nontransgenic mice, this was not due to the absence of the putative target cell (the B-1 cell compartment) or due to a general defect in the B-cell lineage in the absence of RhoH. Rather, it suggests a specific defect in the survival or proliferation of the leukemic cell, associated with an alteration in a biochemical pathway regulated by RhoH. Thus, in our model, CD5 þ IgM þ splenocytes in Em-TCL1 Tg ;Rhoh À/À mice showed increased levels of apoptosis compared with their Em-TCL1 Tg ;Rhoh þ / þ counterparts.
Consistent with this hypothesis, activation of AKT (measured by Ser473 phosphorylation) and ERK in response to BCR crosslinking was significantly decreased in Em-TCL1 Tg ;Rhoh À/À splenocytes compared with their RhoH-expressing counterparts. This is in contrast to nontransgenic, normal splenic B cells, where activation of AKT and ERK downstream the BCR was unaffected by the loss of RhoH. The mechanism underlying this observation, and whether it is dependent on ZAP70, is currently unknown. Although TCL1 is a positive regulator of AKT activation, 30 it seems unlikely that this is due to a direct regulation of TCL1 by RhoH, because the mechanism by which TCL1 activates AKT does not depend on AKT phosphorylation at Ser473 and seems to occur at the level of nuclear translocation of AKT. 30 Regardless of the specific mechanism, these findings appear to be relevant to the pathogenesis of CLL, taking into consideration that (1) AKT is a critical regulator of cell survival, and accumulation of CLL cells has typically been attributed to their ability to escape apoptosis; (2) BCR signaling has been implicated in the pathogenesis of CLL, and this disease has been hypothesized to be initiated and driven by antigen stimulation (reviewed by Chiorazzi et al. 1 ).
Taken together, our data strongly suggest that RhoH has a function in the initiation and/or progression of CLL. This report provides direct experimental evidence implicating RhoH in a malignant process and defines the function of a member of the Rho GTPase family in CLL. The fact that RhoH inactivation impairs B-cell leukemogenesis, although not substantially affecting normal B-cell development and function, makes RhoH a potentially attractive target for the treatment of this disease.
